| Document Date: 2014-08-11 09:42:48
Open Document File Size: 48,30 KBShare Result on Facebook
Company Intersect ENT Inc. / / Country United States / / Currency USD / / Event FDA Phase / / Facility University of Calgary / / IndustryTerm treatment protocols / healthcare system / / MedicalCondition chronic infections / refractory chronic sinusitis / inflammation / chronic sinusitis / inflammatory condition leading / / MedicalTreatment treatment protocols / Sinus surgery / surgical treatment / surgery / Head and Neck Surgery / / Organization FDA / University of Calgary / National Institute of Health / Department of Surgery / Division of Otolaryngology / / Person Lisa Earnhardt / Luke Rudmik / / Position lead author / Clinical Assistant Professor / Head / Chronic Sinusitis Study Author / president and CEO / / Product mometasone furoate / PROPEL® / / ProvinceOrState California / / Technology treatment protocols / /
SocialTag |
Study Indicates Cost Effectiveness of Intersect ENT’s PROPEL Implant for Chronic Sinusitis Study Author Assesses Significant Productivity Loss from Chronic Sinusitis Menlo Park, Calif. – Aug 11, 2014 – Intersect EN